Simulations Plus, Inc. (SLP) Dividend History

Simulations Plus, Inc. (SLP) is a software company specializing in developing pharmacometric and pharmacokinetic modeling and simulation tools for the pharmaceutical, biotech, and health care industries. Founded in 1996, the company provides solutions that aid in drug discovery, development, and regulatory approval processes, with a focus on optimizing clinical trial design and understanding drug behavior. Its flagship products include GastroPlus, ABLAs, and other modeling platforms used by scientists and researchers worldwide.

42505 10th Street West, Lancaster, CA, 93534-7059
Phone: 661-723-7723
Website: https://www.simulations-plus.com

Dividend History

Pay Date	Amount	Ex Dividend Date	Record Date
August 05, 2024	$0.06	07/29/2024	07/29/2024
May 06, 2024	$0.06	04/26/2024	04/29/2024
February 05, 2024	$0.06	01/26/2024	01/29/2024
November 06, 2023	$0.06	10/27/2023	10/30/2023
August 07, 2023	$0.06	07/28/2023	07/31/2023
May 01, 2023	$0.06	04/21/2023	04/24/2023
February 06, 2023	$0.06	01/27/2023	01/30/2023
November 07, 2022	$0.06	10/28/2022	10/31/2022
August 01, 2022	$0.06	07/22/2022	07/25/2022
May 02, 2022	$0.06	04/22/2022	04/25/2022
February 07, 2022	$0.06	01/28/2022	01/31/2022
November 01, 2021	$0.06	10/22/2021	10/25/2021
August 02, 2021	$0.06	07/23/2021	07/26/2021
May 03, 2021	$0.06	04/23/2021	04/26/2021
February 01, 2021	$0.06	01/22/2021	01/25/2021
November 02, 2020	$0.06	10/23/2020	10/26/2020
August 03, 2020	$0.06	07/24/2020	07/27/2020
May 01, 2020	$0.06	04/23/2020	04/24/2020
February 03, 2020	$0.06	01/24/2020	01/27/2020
November 01, 2019	$0.06	10/24/2019	10/25/2019
August 01, 2019	$0.06	07/24/2019	07/25/2019
May 01, 2019	$0.06	04/23/2019	04/24/2019
February 01, 2019	$0.06	01/24/2019	01/25/2019
November 08, 2018	$0.06	10/31/2018	11/01/2018
August 02, 2018	$0.06	07/25/2018	07/26/2018
May 02, 2018	$0.06	04/24/2018	04/25/2018
February 02, 2018	$0.06	01/25/2018	01/26/2018
November 20, 2017	$0.06	11/10/2017	11/13/2017
August 04, 2017	$0.05	07/26/2017	07/28/2017
May 15, 2017	$0.05	05/04/2017	05/08/2017
February 06, 2017	$0.05	01/26/2017	01/30/2017
November 17, 2016	$0.05	11/08/2016	11/10/2016
August 18, 2016	$0.05	08/09/2016	08/11/2016
May 09, 2016	$0.05	04/28/2016	05/02/2016
February 05, 2016	$0.05	01/27/2016	01/29/2016
November 16, 2015	$0.05	11/05/2015	11/09/2015
July 30, 2015	$0.05	07/21/2015	07/23/2015
May 18, 2015	$0.05	05/07/2015	05/11/2015
February 02, 2015	$0.05	01/22/2015	01/26/2015
November 14, 2014	$0.05	11/05/2014	11/07/2014
August 11, 2014	$0.05	07/31/2014	08/04/2014
May 16, 2014	$0.05	05/07/2014	05/09/2014
February 24, 2014	$0.05	02/12/2014	02/17/2014
November 15, 2013	$0.04	11/06/2013	11/08/2013
August 15, 2013	$0.03	08/08/2013	08/12/2013
May 10, 2013	$0.03	05/03/2013	05/07/2013
December 28, 2012	$0.14	12/20/2012	12/24/2012
November 13, 2012	$0.05	11/06/2012	11/08/2012
August 10, 2012	$0.05	08/03/2012	08/07/2012
May 08, 2012	$0.05	04/25/2012	04/27/2012
March 01, 2012	$0.05	02/16/2012	02/21/2012

Dividends Summary

Simulations Plus, Inc. has issued 51 dividend payments over the past 12 years
The most recent dividend was paid 306 days ago, on August 5, 2024
The first recorded dividend was paid on March 1, 2012
The highest dividend payout was $0.14 per share
The average dividend over this 12 year span is $0.06 per share
Simulations Plus, Inc. has increased its dividend payments by 20.00% since 2012

Company News

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

The FDA announced a major shift towards adopting human-relevant and technologically advanced testing methods, including AI-based simulations and lab-grown organoids, to evaluate monoclonal antibody therapies and other drugs, reducing the reliance on traditional animal testing.

Benzinga

Featured Companies: CERT CRL
Healthcare and Medical Simulation Market Size Expected to Reach USD 7.04 Bn by 2034

The global healthcare and medical simulation market is expected to grow significantly from $2.38 billion in 2024 to $6.32 billion by 2033, driven by the increasing demand for effective training methods and the focus on patient safety.

GlobeNewswire Inc.
Biosimulation Industry Forecast, 2029: Analysis of Case Studies, Market Dynamics, Regional Growth Trends, Regulatory Landscape, Value Chain, and Competitive Intelligence

The biosimulation market is projected to reach USD 9.18 billion by 2029, growing at a CAGR of 16.7% from 2024 to 2029. The market is driven by the increasing need for cost and time reduction in the drug development process, but high costs of biosimulation technologies remain a restraint.

GlobeNewswire Inc.

Featured Companies: ANSS CERT SDGR
JMP Securities covers Simulations Plus stock, noting drug development involvement - Investing.com

JMP Securities initiated coverage on Simulations Plus stock, assigning a Market Perform rating. The company is recognized for its substantial experience in Model Informed Drug Development (MIDD) and its balanced approach of robust organic growth and strategic acquisitions.

Investing.com
Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates - Zacks Investment Research

Simulations Plus, Inc. reported third-quarter fiscal 2024 adjusted earnings that declined 9.5% year-over-year but topped the Zacks Consensus Estimate. The company's top line increased 14% year over year, primarily due to higher software revenues. Simulations Plus has also opted to discontinue the quarterly cash dividend and redirect these funds towards growth initiatives.

Zacks Investment Research

Featured Companies: ANET NVDA WWD

Dividend data last updated 06/07/2025 15:36:03 UTC